medigraphic.com
ISSN 2307-2113 (Electronic)
Revista Cubana de Información en Ciencias de la Salud (ACIMED)

2021, Number 2

<< Back Next >>

Revista Cubana de Información en Ciencias de la Salud (ACIMED) 2021; 32 (2)

Analysis of international scientific production about treatments against COVID-19

Ortiz NR, Stable RY

Language: Spanish
References: 43
Page: 1-26
PDF size: 657.83 Kb.


ABSTRACT

The present work aimed to characterize the scientific production on treatments against COVID-19 registered in the SCOPUS database in the period 2019 - June 2020. A bibliometric study was carried out in 842 articles on treatments against COVID-19 available in the SCOPUS database, as well as an analysis of the productivity of authors, countries, institutions, journals, collaboration networks and topics. In scientific production the English language predominated, multiple authorship, publication in first quartile journals in Scimago and a high index of national scientific collaboration was registered. The analysis of co-occurrence of terms yielded three large thematic groups, the main emerging focuses of research on treatments against COVID-19, related to the characterization of the main symptoms of the disease, the proposed treatments and the clinical results of treatments in women and adults with comorbidity. The international scientific production on treatments against COVID-19 shows a sustained growth rate in response to the search for solutions to reduce the fatality rates from SARS-CoV-2. It is characterized by the predominance of national scientific collaboration, publication in high-impact journals with great international visibility. International collaboration between researchers specialized in treatments against the disease should be strengthened to achieve higher quality results.


REFERENCES

  1. World Health Organization. WHO Director-General's opening remarks at themedia briefing on COVID-19. WHO; 2020 [acceso: 20/05/2020]. Disponible en:https://www.who.int/dg/speeches/detail/who-director-general-s-openingremarks-at-the-media-briefing-on-covid-19---3-march-2020

  2. Zhou W. The Coronavirus Prevention Handbook. New York: SkyhorsePublishing; 2020.

  3. Duran P, Berman S, Niermeyer S, Jaenisch T, Forster T, Gómez Ponce deLeón R, et al. COVID-19 and newborn health: systematic review. Rev PanamSalud Publ. 2020;44:e54. DOI: https://doi.org/10.26633/RPSP.2020.54

  4. Johns Hopkins University. Coronavirus Resource Center. Johns HopkinsUniversity; 2020 [acceso: 10/08/2020]. Disponible en:https://coronavirus.jhu.edu

  5. Gregorio-Chaviano O, Limaymanta CH, López-Mesa EK. Análisis bibliométricode la producción científica latinoamericana sobre COVID-19. Biomédica. 2020[acceso: 10/06/2020];40(Supl. 2). Disponible en:https://revistabiomedica.org/index.php/biomedica/article/view/5571

  6. Chahrour M, Assi S, Bejjani M, Nasrallah AA, Salhab H, Fares MY, et al. Abibliometric analysis of Covid-19 research activity: A call for increased output.Cureus. 2020;12:e7357. DOI: https://doi.org/doi:10.7759/cureus.7357

  7. Lou J, Tian SJ, Niu SM, Kang XQ, Lian HX, Zhang LX, et al. Coronavirus disease2019: a bibliometric analysis and review. Eur Rev Med Pharmacol Sci.2020;24:3411-21. DOI: https://doi.org/10.26355/eurrev_202003_20712

  8. Ortiz-Núñez R. Análisis métrico de la producción científica sobre COVID-19en SCOPUS (2019-abril 2020). Rev Cubana Inform Cienc Salud. 2020 [acceso:25/06/2020];31(3). Disponible en:http://www.acimed.sld.cu/index.php/acimed/article/view/1587

  9. Torres-Salinas D. Ritmo de crecimiento diario de la producción científicasobre Covid-19. Análisis en bases de datos y repositorios en acceso abierto. ElProfes Inform. 2020;29:e290215. DOI:https://doi.org/10.3145/epi.2020.mar.15

  10. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. PharmacologicTreatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA.2020;323(18):1824-36. DOI: https://doi.org/10.1001/jama.2020.6019

  11. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al.Infectious Diseases Society of America Guidelines on the Treatment andManagement of Patients with COVID-19. Clin Infect Dis. 2020;478. DOI:https://doi.org/10.1093/cid/ciaa478

  12. Estella Á, Garnacho-Montero J. Del empirismo a la evidencia científica enel tratamiento con antivíricos en los casos graves de infección por coronavirusen tiempos de epidemia. Med Intens. 2020;44(8):509-12. DOI:https://doi.org/10.1016/j.medin.2020.04.009

  13. Quintana PB, Rosales C, Vivas Francesconi G, Novaes CC, Rocha VPS, RochaTAH. Análisis de la producción de conocimiento de los egresados de laespecialización en salud de la familia del Programa Mais Médicos. Rev PanamSalud Públ. 2020;44:e37. DOI:https://doi.org/10.26633/RPSP.2020.37

  14. Mongeon P, Paul-Hus A. The journal coverage of Web of Science and Scopus:a comparative analysis. Scientometrics. 2016;106(1):213-28.

  15. Sweileh WM, Al‑Jabi SW, Sawalha AF, AbuTaha AS, Zyoud SH. Bibliometricanalysis of medicine-related publications on poverty (2005–2015). SpringerPlus.2016;5:1888. DOI: http://doi.org/10.1186/s40064-016-3593-3

  16. Aria M, Cuccurullo C. Bibliometrix: An R-tool for comprehensive sciencemapping analysis. J Informetrics. 2017;11(4):959-75. DOI:http://dx.doi.org/10.1016/j.joi.2017.08.007

  17. Lotka AJ. The frequency distribution of scientific productivity. J WashingAcadem Sciences. 1926;16(12):317-23.

  18. Bradford SC. Sources of information on specific subjects. Engineering.

  19. 1934;137(3550):85-6.19. Sugimoto CR, Larivière V. Measuring research. What everyone needs toknow. New York: Oxford University Press; 2018.

  20. Antwi-Amoabeng D, Kanji Z, Ford B, Beutler BD, Riddle MS, Siddiqui F.Clinical outcomes in COVID-19 patients treated with tocilizumab: An individualpatient data systematic review. J Med Virol. 2020. DOI:https://doi.org/10.1002/jmv.26038

  21. Ding H, Deng W, Ding L, Ye X, Yin S, Huang W. Glycyrrhetinic acid and itsderivatives as potential alternative medicine to relieve symptoms innonhospitalized COVID-19 patients. J Med Virol. DOI:https://doi.org/10.1002/jmv.26064

  22. Hadadi A, Mortezazadeh M, Kolahdouzan K, Alavian G. Does recombinanthuman erythropoietin administration in critically ill COVID-19 patients havemiraculous therapeutic effects? J Med Virol. 2020;92(7):915-8. DOI:https://doi.org/10.1002/jmv.25839

  23. Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment withribavirin: Groundwork for an evaluation concerning COVID-19. J Med Virol.2020;92(7):740-6. DOI: https://doi.org/10.1002/jmv.25798

  24. Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M,Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020;1-9. DOI:https://doi.org/10.1002/jmv.25961

  25. Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19patients in Wuhan, China. J Med Virol. 2020;1-12. DOI:https://doi.org/10.1002/jmv.25882

  26. Cour M, Ovize M, Argaud L. Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure? Crit Care. 2020;24(1):276. DOI:https://doi.org/10.1186/s13054-020-03014-1

  27. Ingraham NE, Boulware D, Sparks MA, et al. Shining a light on the evidencefor hydroxychloroquine in SARS-CoV-2. Crit Care. 2020;24(1):182. DOI:https://doi.org/10.1186/s13054-020-02894-7

  28. Wang Y, Zhou F, Zhang D, et al. Evaluation of the efficacy and safety ofintravenous remdesivir in adult patients with severe COVID-19: study protocolfor a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.Trials. 2020;21(1):422. DOI: https://doi.org/10.1186/s13063-020-04352-9

  29. Zhang Q, Wang Y, Qi C, Shen L, Li J. Clinical trial analysis of 2019-nCoVtherapy registered in China. J Med Virol. 2020;92(6):540-5. DOI:https://doi.org/10.1002/jmv.25733

  30. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: Asystematic review. J Med Virol. 2020;92(5):479-90. DOI:https://doi.org/10.1002/jmv.25707

  31. Al-Tawfiq JA, Memish ZA. COVID-19 in the Eastern Mediterranean Regionand Saudi Arabia: prevention and therapeutic strategies. Int J AntimicrobAgents. 2020;55(5):105968. DOI:https://doi.org/10.1016/j.ijantimicag.2020.105968

  32. de Oliveira PG, Termini L, Durigon EL, Lepique AP, Sposito AC, Boccardo E.Diacerein: A potential multi-target therapeutic drug for COVID-19. MedHypotheses. 2020;144:109920. DOI:https://doi.org/10.1016/j.mehy.2020.109920

  33. Fantini J, Chahinian H, Yahi N. Synergistic antiviral effect ofhydroxychloroquine and azithromycin in combination against SARS-CoV-2: Whatmolecular dynamics studies of virus-host interactions reveal. Int J AntimicrobAgents. 2020;106020. DOI: https://doi.org/10.1016/j.ijantimicag.2020

  34. Huang F, Li Y, Leung EL, et al. A review of therapeutic agents and Chineseherbal medicines against SARS-COV-2 (COVID-19). Pharmacol Res.2020;158:104929. DOI: https://doi.org/10.1016/j.phrs.2020.104929

  35. Luo P, Liu D, Li J. Pharmacological perspective: glycyrrhizin may be anefficacious therapeutic agent for COVID-19. Int J Antimicrob Agents.2020;55(6):105995. DOI: https://doi.org/10.1016/j.ijantimicag.2020.105995

  36. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. PharmacologicTreatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA.2020;323(18):1824–36. DOI: https://doi.org/10.1001/jama.2020.6019

  37. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: arandomised, double-blind, placebo-controlled, multicentre trial. Lancet.2020;395(10236):1569-78. DOI: https://doi.org/10.1016/S0140-6736(20)31022-9

  38. Kwiek M. The internationalization of research in Europe: A quantitativestudy of 11 national systems from a micro-level perspective. J Stud InternatEduc. 2015;19(4):341-59.

  39. Pacheco-Mendoza J, Alhuay-Quispe J. Unidades de Bibliometría, espaciosnecesarios para el monitoreo de producción científica en la universidadmoderna. Rev Haban Cienc Méd. 2019 [acceso: 20/07/2020];18(3):376-80.Disponible en:http://www.revhabanera.sld.cu/index.php/rhab/article/view/2874

  40. Dumas-Mallet E, Garenne A, Boraud T, Gonon F. Does newspapers coverageinfluence the citations count of scientific publications? An analysis ofbiomedical studies. Scientometrics. 2020;123:413-27. DOI:https://doi.org/10.1007/s11192-020-03380-1

  41. The Lancet. COVID-19 vaccines: no time for complacency. Lancet.2020;396(10263):1607. DOI: https://doi.org/10.1016/S0140-6736(20)32472-7

  42. Koirala A, Joo YJ, Khatami A, Chiu C, Britton PN. Vaccines for COVID-19:The current state of play. Paediatr Respir Rev. 2020;35:43-9. DOI:https://doi.org/10.1016/j.prrv.2020.06.010

  43. Al-Kassmy J, Pedersen J, Kobinger G. Vaccine Candidates againstCoronavirus Infections. Where Does COVID-19 Stand? Viruses. 2020;12(8):861.DOI: https://doi.org/10.3390/v12080861




2020     |     www.medigraphic.com